Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The investigators will study whether the drug tadalafil improves shortness of breath in 126
Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the
lungs. The investigators will also assess whether tadalafil improves quality of life, home
daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood
pressure in the lungs, and lung function. Veterans who enroll in the trial will be allocated
by chance to either active tadalafil or an inactive identical capsule (placebo). Neither the
Veteran nor the investigator will know whether the Veteran is taking tadalafil or placebo.
Veterans will be followed closely in clinic or by telephone at 1, 2, 3, 4, 5, and 6 months,
with attention to side effects and safety. At 1,3, and 6 months the investigators will repeat
the questionnaires and testing of blood pressures in the lung and lung function. The
investigators anticipate that the results of this study will determine whether tadalafil
improves shortness of breath when added to usual medications for COPD.
Phase:
Phase 2
Details
Lead Sponsor:
VA Office of Research and Development
Collaborators:
Atlanta VA Medical Center VA Boston Healthcare System VA Eastern Colorado Health Care System VA Nebraska Western Iowa Health Care System